32,639 Shares in Zoetis Inc. (NYSE:ZTS) Acquired by Picton Mahoney Asset Management

Picton Mahoney Asset Management acquired a new position in Zoetis Inc. (NYSE:ZTS) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 32,639 shares of the company’s stock, valued at approximately $5,319,000.

Several other hedge funds also recently added to or reduced their stakes in the business. Midwest Professional Planners LTD. lifted its stake in Zoetis by 9.4% during the fourth quarter. Midwest Professional Planners LTD. now owns 3,185 shares of the company’s stock worth $519,000 after purchasing an additional 273 shares in the last quarter. Intact Investment Management Inc. acquired a new position in Zoetis during the fourth quarter worth $65,000. Atala Financial Inc acquired a new position in Zoetis during the fourth quarter worth $60,000. LBP AM SA lifted its stake in Zoetis by 19.6% during the fourth quarter. LBP AM SA now owns 112,801 shares of the company’s stock worth $18,379,000 after purchasing an additional 18,483 shares in the last quarter. Finally, PGGM Investments lifted its stake in Zoetis by 91.8% during the fourth quarter. PGGM Investments now owns 58,528 shares of the company’s stock worth $9,536,000 after purchasing an additional 28,005 shares in the last quarter. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts have commented on the company. Leerink Partners assumed coverage on Zoetis in a research note on Monday, December 2nd. They set an “outperform” rating and a $215.00 price target on the stock. Piper Sandler upped their price target on Zoetis from $200.00 to $205.00 and gave the stock an “overweight” rating in a research note on Thursday, February 27th. StockNews.com upgraded Zoetis from a “hold” rating to a “buy” rating in a research note on Friday, March 7th. Leerink Partnrs upgraded Zoetis to a “strong-buy” rating in a research note on Monday, December 2nd. Finally, Morgan Stanley reduced their price objective on Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a research note on Friday, February 14th. One analyst has rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Zoetis has a consensus rating of “Buy” and a consensus target price of $215.90.

Zoetis Trading Up 0.8 %

Shares of Zoetis stock opened at $161.33 on Friday. Zoetis Inc. has a 12-month low of $144.80 and a 12-month high of $200.33. The stock has a market cap of $72.24 billion, a price-to-earnings ratio of 29.49, a PEG ratio of 2.78 and a beta of 0.94. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09. The company has a fifty day simple moving average of $166.82 and a 200-day simple moving average of $176.15.

Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, February 13th. The company reported $1.40 EPS for the quarter, beating analysts’ consensus estimates of $1.37 by $0.03. The business had revenue of $2.32 billion for the quarter, compared to analysts’ expectations of $2.30 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. On average, equities analysts forecast that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be issued a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.24%. The ex-dividend date is Monday, April 21st. Zoetis’s dividend payout ratio is currently 36.56%.

Insider Activity at Zoetis

In other news, Director Willie M. Reed sold 1,210 shares of Zoetis stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total value of $201,029.40. Following the sale, the director now owns 11,245 shares of the company’s stock, valued at $1,868,244.30. The trade was a 9.71 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Roxanne Lagano sold 326 shares of Zoetis stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total transaction of $55,804.68. Following the completion of the sale, the executive vice president now directly owns 16,107 shares in the company, valued at approximately $2,757,196.26. The trade was a 1.98 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 1,862 shares of company stock worth $312,254 in the last quarter. Company insiders own 0.16% of the company’s stock.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.